The 10-K/A is purely a disclosure enhancement, not a financial event — no stock-moving catalyst. Monitor Phase 2 endometrial cancer topline data at year-end 2026 and interim Phase 1b breast cancer data in 2027 for meaningful catalysts. Competitive risk from Celcuity's gedatolisib PDUFA date of July 17, 2026 warrants attention.
Price Chart
Executive Summary
Sensei Biotherapeutics filed Amendment No. 1 to its 2025 Form 10-K solely to revise Part I Item 1 (Business) in response to SEC staff comments. The amendment expands disclosure around the February 2026 acquisition of Faeth Therapeutics (including its lead asset PIKTOR), the $200M private placement, clinical trial details, and competitive landscape. No financial statements were amended, no restatements were made, and the original financial data remains unchanged.
Key Facts
- Amendment filed solely to revise Business section (Item 1) in response to SEC staff comments
- No financial statements, restatements, or auditor changes were made
- Original 10-K filed March 30, 2026; amendment filed June 2, 2026
- Revised Section 302 certifications (Exhibits 31.3, 31.4) filed with paragraphs 3-5 omitted since no financial or control changes
- Acquisition of Faeth Therapeutics closed February 17, 2026, bringing PIKTOR (oral PI3K/AKT/mTOR inhibitor) into pipeline
- Received $200M gross proceeds from private placement to fund PIKTOR development
- Phase 2 endometrial cancer trial (FTH-PIK-201) topline data expected year-end 2026
- Phase 1b HR+/HER2- breast cancer trial (FTH-PIK-101) first patient dosed May 2026
- Patent portfolio for PIKTOR includes 13 issued U.S. patents with expiration between 2027-2046
- Takeda milestone obligations: up to $119M development/regulatory milestones + up to $250M sales milestones for PIKTOR
Financial Impact
No financial restatement or revision. Filing is administrative — expands business description and pipeline disclosure only.
Risk Factors
- Direct competition from gedatolisib (Celcuity) with FDA decision expected July 17, 2026, and other PI3K/AKT/mTOR candidates in development
- Clinical trial execution risk — PIKTOR data readouts for endometrial (year-end 2026) and breast cancer (2027) may disappoint
- Reliance on Takeda-licensed assets with milestone obligations ($119M + $250M) creating significant future cash commitments if successful
- Pre-revenue clinical-stage biotech with $27M market cap and history of restructuring (65% workforce reduction in Nov 2025)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-252637 |
| Document: d130328dex313.htm | 0001193125-26-252637 |
| Document: d130328dex314.htm | 0001193125-26-252637 |
| Document: 0001193125-26-252637-index-headers.html | 0001193125-26-252637 |
| Document: 0001193125-26-252637-index.html | 0001193125-26-252637 |
| Document: 0001193125-26-252637.txt | 0001193125-26-252637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 18w ago | 3 | $13.86 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 8-K | $13.04 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | EFFECT | $13.04 | awaiting T+5 | — | — |
Jun 10, 2026 19w ago | S-3/A | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 10, 2026 19w ago | 8-K | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 2, 2026 21w ago | 10-K/A | $16.10 $12.63 | ▼ −21.53% | ▼ −18.56% | — |
Jun 2, 2026 21w ago | S-3/A | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
Jun 1, 2026 21w ago | Insider Cluster | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
May 22, 2026 22w ago | DEFA14A | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
May 22, 2026 22w ago | 8-K | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers